+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A phase II study of vinorelbine , cisplatin and 5-fluorouracil in patients with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck



A phase II study of vinorelbine , cisplatin and 5-fluorouracil in patients with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck



European Journal of Cancer 35(SUPPL 4): S176, Sept




(PDF emailed within 1 workday: $29.90)

Accession: 034314169

Download citation: RISBibTeXText


Related references

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. Annals of Oncology 6(10): 987-991, 1995

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer 85(4): 952-959, Feb 15, 1999

A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head and Neck 24(12): 1054-1059, 2002

Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. Oncology Letters 4(5): 898-904, 2012

Cisplatin, raltitrexed, levofolinic acid 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head neck: A phase II randomized study. Oncology 63(3): 232-238, 2002

Cisplatin, Raltitrexed, Levofolinic Acid and 5-Fluorouracil in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase Ii Randomized Study. Oncology 63(3): 232-238, 2002

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. Oncology 63(3): 232-238, 2002

Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer ChemoTherapy and Pharmacology 66(4): 729-736, 2010

Phase I-II study with docetaxel , cisplatin and 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. European Journal of Cancer 35(SUPPL 4): S164, Sept, 1999

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Annals of Oncology 10(1): 119-122, 1999

Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology 10(1): 119-122, 1999

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced squamous cell carcinoma of the head and neck. British Journal of Cancer 90(2): 348-352, 26 January, 2004

Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. International Journal of Clinical Oncology 9(3): 161-166, 2004

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). British Journal of Cancer 90(2): 348-352, 2004

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). Annals of Oncology 11(5): 575-580, 2000